Overview

A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

Status:
NOT_YET_RECRUITING
Trial end date:
2029-03-31
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the efficacy and safety of SHR-A1811 and Fulvestrant in Combination with or without HS-10352 in locally advanced or metastatic breast cancer patients. Subjects will receive SHR-A1811 and Fulvestrant in Combination with or without HS-10352.
Phase:
PHASE1
Details
Lead Sponsor:
Henan Cancer Hospital